Walgreens tapped for AARP’s retail drug store program
DEERFIELD, Ill. — Walgreens and AARP are expanding their relationship with a new retail drug store program that will provide AARP members with exclusive offers and rewards, and includes member and community outreach to promote health and wellness.
The program will run for three years and builds on an already-established relationship between the two, which have collaborated on several initiatives since 2006.
“AARP is pleased to select Walgreens to provide a retail drug store program offering unique values on important health-and-wellness products and services. We are taking our relationship to a new level on behalf of our members representing America’s growing population of people over 50,” AARP CEO A. Barry Rand said.
The retail drug store program includes the following benefits:
AARP membership card offers: AARP members show their AARP membership cards at Walgreens registers and receive monthly and weekly offers for exclusive values on in-store purchases. Additional benefits will be announced later in 2012;
AARP online discount: AARP members can shop with an exclusive online discount available at a co-branded microsite, Aarp.walgreens.com; and
Pharmacy benefits: Walgreens is developing program services for AARP members focused on the pharmacy experience, including accessing pharmacists by phone, online chat and in-person interactions. Additional benefits could include education and tools to help members manage new prescriptions. These programs will be tested throughout 2012 for potential national rollout. Additionally, AARP members will receive special preventive health offers throughout the year.
“As the nation’s largest community pharmacy with the most 24-hour locations, a growing range of pharmacy, health-and-wellness services and constant innovations to deliver cost-effective care, Walgreens is essential to AARP members," Walgreens president and CEO Greg Wasson said. "We are proud to work with AARP in improving the health and wellness of people over 50, so we are excited to be selected to provide the retail drug store program that carries the AARP name and to take our relationship into the future. Millions of Americans over 50 choose Walgreens for their health and daily living needs, and we are pleased to provide AARP’s members with extra rewards, offers and services."
The program also is supported by:
Walgreens Way to Well Health Tour with AARP: With a combined goal of screening approximately 100,000 people annually in the country’s medically underserved areas with a high prevalence of chronic disease, this effort includes the Walgreens Way to Well Health Tour with AARP and the Walgreens Way to Well Community Health Events with AARP. The tour is comprised of four buses with trained staff delivering six free health tests in underserved communities. The Walgreens Way to Well Community Health Events with AARP also include free health tests delivered by Walgreen pharmacists and are hosted by local Walgreens stores. Both programs provide a free AARP annual membership to all participants.
“The AARP/Walgreens Wellness Tour proved successful in bringing more than $60 million in free health tests to communities across America during the past three years, and we are looking forward to bringing a new tour, the Walgreens Way to Well Health Tour with AARP, to many more Americans, particularly in medically underserved areas of the country,” Rand said.
FDA approves two new drugs for pancreatic disorders
SILVER SPRING, Md. — The Food and Drug Administration has approved two new drugs for pancreatic disorders, the agency said Thursday.
The FDA announced the approval of Aptalis Pharma’s Ultresa and Viokase, both generically known as pancrelipase. Ultresa is a delayed-release capsule for children and adults with cystic fibrosis, which affects the lungs and other organs, while Viokase is meant for use with a proton-pump inhibitor in adults who can’t digest food because of pancreatitis or surgical removal of the pancreas.
"The approvals of Ultresa and Viokase, along with the other approved pancreatic enzyme products, allow healthcare providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency," Office of Drug Evaluation III director Julie Beitz said.
FDA approves first flu vaccine to treat four strains of virus
SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the first flu vaccine to prevent four strains of the influenza virus.
The agency announced Wednesday the approval of MedImmune’s FluMist Quadrivalent, which contains two influenza A and two influenza B strains. The currently approved version of FluMist is trivalent, containing two influenza A strains and one B strain, as are the other FDA-approved vaccines. The FDA said that in any given year, there may be two influenza B strains, or the strain in the vaccine may not be the one circulating.
"Illness caused by influenza B virus affects children, particularly young and school-aged, more than any other population," FDA Center for Biologics Evaluation and Research director Karen Midthun said. "A vaccine containing the four virus strains most likely to spread and cause illness during the influenza season offers an additional option to aid in influenza prevention efforts."